NYSEAMERICAN:TRXC

TransEnterix Stock Forecast, Price & News

$1.52

-0.22 (-12.64 %)

(As of 04/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.48

Now: $1.52▼

$1.78

50-Day Range

$0.41

MA: $0.53▼

$1.17

52-Week Range

$0.28

Now: $1.52▼

$6.95

Volume13.33 million shs

Average Volume44.56 million shs

Market Capitalization$217.02 million

P/E RatioN/A

Dividend YieldN/A

Beta2.56

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:TRXC

Previous Symbol

CUSIPN/A

CIK876378

Webwww.transenterix.com

Phone+1-919-7658400

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.04

Current Ratio3.24

Quick Ratio2.30

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$8.53 million

Price / Sales25.44

Cash Flow$1.09 per share

Price / Cash Flow1.40

Book Value$2.68 per share

Price / Book0.57

Profitability

EPS (Most Recent Fiscal Year)($4.22)

Net Income$-154,200,000.00

Net Margins-2,149.15%

Return on Equity-83.74%

Return on Assets-64.94%

Miscellaneous

Outstanding Shares142,777,000

Market Cap$217.02 million

Next Earnings DateN/A

OptionableOptionable

Headlines

Global Robotic Surgery Market Report 2020-2024 - Escalating MedTech Research and Development Expenditures - Yahoo Finance
April 12, 2021 | finance.yahoo.com

Global Robotic Surgery Market Report 2020: Insights & Forecast with Potential Impact of COVID-19 to 2024 - ResearchAndMarkets.com - Business Wire
April 8, 2021 | businesswire.com

Asensus Surgical Can't Support This Valuation and Won't Anytime Soon - InvestorPlace
April 4, 2021 | investorplace.com

Asensus Surgical's Name Has Changed, But Investors' Valuation Concerns Haven't - InvestorPlace
April 1, 2021 | investorplace.com

Investing in Asensus Surgical Requires the Patience of a Surgeon - Investorplace.com
April 1, 2021 | investorplace.com

In a Time of Transition, Asensus Surgical Stock Remains a Worthy Investment - InvestorPlace
March 28, 2021 | investorplace.com

Despite Name Change, Asensus Stock Is Still One to Avoid - InvestorPlace
March 28, 2021 | investorplace.com

Despite Name Change, Asensus Stock Is Still One to Avoid - Investorplace.com
March 26, 2021 | investorplace.com

Transenterix Stock Has More Problems Than a Simple Name Change Can Fix - Investorplace.com
March 23, 2021 | investorplace.com

A Name Change Won't Fix the Disaster That Is Asensus Surgical - InvestorPlace
March 10, 2021 | investorplace.com

TransEnterix or Asensus Surgical? Let’s Call the Whole Thing Off - Nasdaq
March 10, 2021 | nasdaq.com

TransEnterix or Asensus Surgical? Let's Call the Whole Thing Off - InvestorPlace
March 8, 2021 | investorplace.com

TransEnterix (TRXC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
March 5, 2021 | finance.yahoo.com

TransEnterix (TRXC) Moves to Buy: Rationale Behind the Upgrade
March 5, 2021 | finance.yahoo.com

Asensus Surgical Announces Finalization of Name and Ticker Symbol Change
March 5, 2021 | finance.yahoo.com

Only Patience Will Be Rewarded With Asensus - InvestorPlace
March 4, 2021 | investorplace.com

TransEnterix Has a Lesson That Reddit Investors Should Take Time to Learn - Nasdaq
March 4, 2021 | nasdaq.com

Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021
March 4, 2021 | finance.yahoo.com

TRXC stock rises after Asensus announces FDA clearance - Seeking Alpha
March 3, 2021 | seekingalpha.com

Asensus Surgical Announces FDA Clearance in General Surgery
March 3, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.71 out of 5 stars

Medical Sector

1265th out of 2,025 stocks

Surgical & Medical Instruments Industry

114th out of 169 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for TransEnterix.

2.3 Community Rank

Outperform Votes
TransEnterix has received 460 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TransEnterix has received 524 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TransEnterix has received 53.25% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote “Outperform” if you believe TRXC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TransEnterix does not currently pay a dividend.
Dividend Growth
TransEnterix does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TransEnterix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.10% of the stock of TransEnterix is held by insiders.
Percentage Held by Institutions
Only 8.22% of the stock of TransEnterix is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for TransEnterix are expected to grow in the coming year, from ($0.74) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TransEnterix is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TransEnterix is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TransEnterix has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$1.52

-0.22 (-12.64 %)

(As of 04/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

Is TransEnterix a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TransEnterix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRXC, but not buy additional shares or sell existing shares.
View analyst ratings for TransEnterix or view top-rated stocks.

What stocks does MarketBeat like better than TransEnterix?

Wall Street analysts have given TransEnterix a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TransEnterix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) announced its quarterly earnings results on Thursday, November, 5th. The medical instruments supplier reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.11. The medical instruments supplier had revenue of $0.81 million for the quarter, compared to analysts' expectations of $0.73 million. TransEnterix had a negative trailing twelve-month return on equity of 83.74% and a negative net margin of 2,149.15%.
View TransEnterix's earnings history.

Who are TransEnterix's key executives?

TransEnterix's management team includes the following people:

Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Who are some of TransEnterix's key competitors?

Some companies that are related to TransEnterix include Surmodics (SRDX), OraSure Technologies (OSUR), Intersect ENT (XENT), Antares Pharma (ATRS), Invo Bioscience (IVOB), Anika Therapeutics (ANIK), SeaSpine (SPNE), Vapotherm (VAPO), Pulse Biosciences (PLSE), Accuray (ARAY), iCAD (ICAD), InfuSystem (INFU), AVITA Medical (RCEL), Cytosorbents (CTSO) and Profound Medical (PROF).
View all of TRXC's competitors.

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), Actinium Pharmaceuticals (ATNM), XOMA (XOMA), Geron (GERN), OPKO Health (OPK), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $1.52.

How much money does TransEnterix make?

TransEnterix has a market capitalization of $217.02 million and generates $8.53 million in revenue each year. The medical instruments supplier earns $-154,200,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis.

What is TransEnterix's official website?

The official website for TransEnterix is www.transenterix.com.

Where are TransEnterix's headquarters?

TransEnterix is headquartered at 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400 or via email at [email protected]

This page was last updated on 4/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here